News & Updates

In the treatment of patients with drug-resistant focal epilepsy, transdermally administered cannabidiol is well tolerated but is not superior to placebo in terms of reducing seizure frequency, according to a study.

Safety analysis of the phase III MAESTRO-NAFLD-1 trial presented at ILC 2022 demonstrated the potential of resmetirom as a treatment for patients with non-alcoholic steatohepatitis (NASH) who have liver fibrosis.

In the final analysis of the phase III ICON8* study, a weekly dose-dense chemotherapy (CT) regimen comprising paclitaxel and carboplatin did not improve survival outcomes in women with epithelial ovarian cancer** compared with the standard first-line (1L) paclitaxel-carboplatin regimen given once every 3 weeks (Q3W).

Use of pembrolizumab helps maintain or improve health-related quality of life in patients with previously treated, advanced endometrial cancer characterized by high levels of microsatellite instability (MSI) or deficient mismatch repair (MSI-H/dMMR), according to data from the phase II KEYNOTE-158 study.

In the treatment of COVID-19 inpatients, intravenous administration of dexamethasone leads to a shorter hospital stay compared with methylprednisolone, according to a study.